MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2025.01.089

Медицинская библиотека · Journal of the American Academy of Dermatology · 2025

Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study.

Gordon Kenneth B, Augustin Matthias, Barker Jonathan, Tada Yayoi, Lebwohl Mark G, Tang Ming, Hofmann Patrick, Thoma Christian, Gottlieb Alice B

СтатьяРандомизированное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Generalized pustular psoriasis (GPP) is a chronic inflammatory disease with an unpredictable disease course. Long-term treatment goals include sustained resolution of skin symptoms, prevention of new flares, and improvement in quality of life (QoL).

OBJECTIVE

To compare the effect of the interleukin-36 receptor monoclonal antibody spesolimab 600 mg subcutaneous (SC) loading dose (LD) followed by 300 mg SC every 4 weeks (q4w) versus placebo on skin symptoms and QoL burden in patients with GPP.

METHODS

A post hoc analysis of the EFFISAYIL 2 trial (NCT04399837) was conducted to assess the proportion of patients with sustained improvement of skin symptoms (GPP Physician Global Assessment total score, 0 or 1) and QoL burden (Dermatology Life Quality Index score, 0 or 1) at all visits up to week 48.

RESULTS

Among the patients who received spesolimab 600 mg SC LD followed by 300 mg SC q4w, 63.3% had sustained improvement of skin symptoms (vs 29.0%; placebo), and 24.1% had sustained improvement of QoL burden (vs 3.2%; placebo).

LIMITATIONS: Retrospective, descriptive, post hoc analysis.

CONCLUSION

Spesolimab 600 mg SC LD followed by 300 mg SC q4w provides sustained improvement of skin symptoms and QoL burden in a substantially higher proportion of patients with GPP versus placebo.

Для цитирования: Gordon Kenneth B, Augustin Matthias, Barker Jonathan, Tada Yayoi, Lebwohl Mark G, Tang Ming, Hofmann Patrick, Thoma Christian, Gottlieb Alice B. Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study.. Journal of the American Academy of Dermatology. 2025. DOI: 10.1016/j.jaad.2025.01.089.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.